Evidence map›Paper›PMID 32724100›Full record

ArticleScientific reports2020

Model-based optimization of combination protocols for irradiation-insensitive cancers.

Beata Hat, Joanna Jaruszewicz-Błońska, Tomasz Lipniacki

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Beata HatInstitute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland.
Joanna Jaruszewicz-BłońskaInstitute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland.
Tomasz LipniackiInstitute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland. tlipnia@ippt.pan.pl.
Polish Academy of Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternations in the p53 regulatory network may render cancer cells resistant to the radiation-induced apoptosis. In this theoretical study we search for the best protocols combining targeted therapy with radiation to treat cancers with wild-type p53, but having downregulated expression of PTEN or overexpression of Wip1 resulting in resistance to radiation monotherapy. Instead of using the maximum tolerated dose paradigm, we exploit stochastic computational model of the p53 regulatory network to calculate apoptotic fractions for both normal and cancer cells. We consider combination protocols, with irradiations repeated every 12, 18, 24, or 36 h to find that timing between Mdm2 inhibitor delivery and irradiation significantly influences the apoptotic cell fractions. We assume that uptake of the inhibitor is higher by cancer than by normal cells and that cancer cells receive higher irradiation doses from intersecting beams. These two assumptions were found necessary for the existence of protocols inducing massive apoptosis in cancer cells without killing large fraction of normal cells neighboring tumor. The best found protocols have irradiations repeated every 24 or 36 h with two inhibitor doses per irradiation cycle, and allow to induce apoptosis in more than 95% of cancer cells, killing less than 10% of normal cells.

Indexed as

Models, StatisticalAntineoplastic AgentsApoptosisCell ProliferationCells, CulturedChemoradiotherapyDose-Response Relationship, RadiationGamma RaysHumansNeoplasmsProtein Phosphatase 2CProto-Oncogene Proteins c-mdm2PTEN PhosphohydrolaseRadiation ToleranceTumor Suppressor Protein p53Antineoplastic AgentsMDM2 protein, humanPPM1D protein, humanProtein Phosphatase 2CProto-Oncogene Proteins c-mdm2PTEN PhosphohydrolasePTEN protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID32724100
PMCPMC7387345
OpenAlexW3045885407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.